Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...

Key insights from Fall Clinical 2026 on diagnosing and managing inflammatory skin conditions and post-inflammatory dyspigmentation in patients with skin of color.

Key takeaways from the 26th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada were published.

Findings seen among pediatric patients presenting to the emergency department with moderate-to-severe acute pain ...

Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...

Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.

Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.

Nearly 1 in 3 patients with systemic lupus erythematosus (SLE) are taking a supplement–medication combination with potential for an interaction, according to ...

The novel GPR6 inhibitor met its primary endpoint in the phase 3 ARISE trial, achieving a statistically significant reduction in daily OFF time and demonstrating non-dopaminergic motor and ...

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

HealthDay News — Most adolescents with colorectal cancer (CRC) present with advanced disease, and relapse is common, according to a study presented at the annual American Academy of Pediatrics ...